![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 10, 2025
The latest clinical trial findings in breast, lung, nose/sinus, and throat cancers, as well as melanoma and cancer survivorship
March 21, 2025
The changes significantly broaden eligibility and clarify key details in this phase 3 trial exploring whether adding radiation therapy to standard immunotherapy will improve survival in patients with stable disease after initial treatment
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
November 25, 2024
Fall Group Meeting highlights; impactful results in head and neck cancer; a ComboMATCH update
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
August 25, 2023
This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
Summaries of recently published ECOG-ACRIN research results